Terminated/Withdrawn
Sponsor ID
20110209
Evaluation of the Conversion from Peginesatide to Epoetin alfa in Patients Receiving Hemodialysis
Study Details
The purpose of this study is to evaluate whether hemodialysis patients on peginesatide can be converted to epoetin alfa by using a predefined conversion table while achieving a stable hemoglobin.
Protocol Summary
Primary Outcome Measures
Mean hemoglobin during evaluation period
Timeframe: Last 8 weeks of epoetin alfa period
Secondary Outcome Measures
Mean dose of Epoetin alfa during the evaluation period
Timeframe: Last 8 weeks of Epoetin alfa treatment period
Hemoglobin every 2 weeks
Timeframe: Every 2 weeks during peginesatide and Epoetin alfa periods
Dose every 2 weeks
Timeframe: Every 2 weeks during peginesatide and Epoetin alfa periods
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Jackson, TN, United States, 38305
Status
Recruiting
Location
Research Site
Orange, CT, United States, 06477
Status
Recruiting
Location
Research Site
Meridian, ID, United States, 83642
Status
Recruiting
Location
Research Site
Azusa, CA, United States, 91702
Status
Recruiting
Location
Research Site
Phoenix, AZ, United States, 85004
Status
Recruiting
Location
Research Site
Tempe, AZ, United States, 85284
Status
Recruiting
Showing {first} - {last} of {total} Results